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Abstract
 
Immunologically privileged retinal antigens can serve as targets of experimental autoimmune
uveitis (EAU), a model for human uveitis. The tolerance status of susceptible strains, whose target
antigen is not expressed in the thymus at detectable levels, is unclear. Here, we address this issue
directly by analyzing the consequences of genetic deficiency versus sufficiency of a uveitogenic
retinal antigen, interphotoreceptor retinoid-binding protein (IRBP). IRBP-knockout (KO) and
wild-type (WT) mice on a highly EAU-susceptible background were challenged with IRBP.
The KO mice had greatly elevated responses to IRBP, an altered recognition of IRBP epitopes,
and their primed T cells induced exacerbated disease in WT recipients. Ultrasensitive immuno-
histochemical staining visualized sparse IRBP-positive cells, undetectable by conventional assays,
in thymi of WT (but not of KO) mice. IRBP message was PCR amplified from these cells after
microdissection. Thymus transplantation between KO and WT hosts demonstrated that this level
of expression is functionally relevant and sets the threshold of immune (and autoimmune) reactiv-
ity. Namely, KO recipients of WT thymi generated reduced IRBP-specific responses, and WT
recipients of KO thymi developed enhanced responses and a highly exacerbated disease. Reper-
toire culling and thymus-dependent CD25
 
 
 
 T cells were implicated in this effect. Thus, uveitis-
susceptible individuals display a detectable and functionally significant tolerance to their target an-
tigen, in which central mechanisms play a prominent role.
Key words: gene knockout mice • interphotoreceptor retinoid-binding protein • 
thymic selection • uveitis • autoimmunity
 
Introduction
 
Experimental autoimmune uveitis (EAU) is an autoimmune
disease that targets the neural retina. It can be induced in
susceptible animals by immunization with retinal antigens
and serves as a model for human autoimmune uveitis (1).
Uveitogenic antigens are typically derived from the retinal
photoreceptor cells, function in the visual cycle, and are
highly evolutionarily conserved. Examples are arrestin (retinal
soluble antigen [S-Ag]), interphotoreceptor retinoid-binding
protein (IRBP), rhodopsin and its illuminated form opsin,
recoverin, and phosducin (2). Susceptibility to uveitis induced
with these antigens varies among species and among strains
(3). Some strains of mice are susceptible to IRBP, but all are
relatively resistant to S-Ag (3, 4).
The question of tolerance to immunologically privileged
retinal antigens remains elusive. Evidence for peripheral
tolerance is sparse and inconclusive. As part of the immune
privilege of the eye, retinal antigens are largely sequestered
from the immune system by an efficient blood-retinal barrier
and by lack of direct lymphatic drainage of the interior of
the globe. Retina-specific antigens are not found outside
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the eye with the exception of the pineal gland (“third
eye”), whose size is very small and whose contribution as a
peripheral source of antigen is unclear. The phenomenon
known as anterior chamber–associated immune deviation
(ACAID), where antigens introduced into the eye elicit a
deviant response involving regulatory cells and suppression
of delayed hypersensitivity, has been well studied in rela-
tion to injected foreign antigens (5, 6). Although induction
of ACAID to IRBP by its injection into the anterior cham-
ber can protect from EAU (7), it is not at all clear whether
ACAID exists naturally to native retinal antigens present in
the intact eye. Indeed, “unsequestering” IRBP or S-Ag by
expressing them in the periphery induces profound resis-
tance to EAU (8–10), supporting the notion that peripheral
tolerance to antigens residing in the eye is minimal.
On the other hand, recent studies demonstrated expres-
sion in the thymus of some retinal antigens and suggested
an association with EAU resistance. Egwuagu et al. (11)
showed that IRBP is expressed by IRBP-resistant, but not
by susceptible, mouse strains, whereas S-Ag (which does
not elicit EAU in mice) was expressed by all examined
strains. Conversely, AIRE-deficient mice were shown to
lack thymic expression of S-Ag (12). These mice developed
antiretinal antibodies and retinal inflammation as they aged.
Although the antigen specificity of that response has not
been examined, in the aggregate, these studies support the
notion that some retinal antigens can be expressed in the
thymus at levels sufficient to elicit central tolerance. How-
ever, a confounding factor is the multiplicity of retinal anti-
gens, each of which can potentially serve as a target for
uveitis. What follows is that the antigen(s) with the poorest
thymic expression will determine the functional outcome
in terms of antiretinal autoimmunity. In uveitis-susceptible
individuals, the extent of thymic expression and of central
tolerance to their particular target antigen is unclear.
In the present study, we address this issue directly by an-
alyzing the consequences of genetic IRBP deficiency ver-
sus sufficiency on immunological responses to this antigen
and its ability to induce uveitis. Using highly sensitive
methods and thymic transplantation, we demonstrate that
EAU-susceptible WT mice express IRBP in the thymus
and display a detectable and functionally significant level of
tolerance to this antigen in which central selection mecha-
nisms play a major role. These data provide direct evidence
that, in uveitis-susceptible individuals, central tolerance sets
the threshold of autoimmune reactivity to their target anti-
gen and provides new insights into self-tolerance to immu-
nologically privileged retinal antigens.
 
Materials and Methods
 
Mice.
 
The highly EAU-susceptible B10.RIII mice (H-2
 
r
 
)
were purchased from Jackson Labs. IRBP-knockout (KO) mice,
lacking the promoter region and 81% of the IRBP coding se-
quence, were generated as described (13) and were backcrossed
onto the B10.RIII background for 10 generations. Mice were
used between the ages of 8 and 12 wk. No difference in disease
susceptibility between males and females was noted. Treatment
 
of animals was in compliance with Institutional Guidelines and all
animal study protocols were approved by an Institutional Review
Board.
 
Antigens, Antibodies, and Reagents.
 
Native bovine IRBP and
recombinant repeat 1 of human IRBP (rIRBP) were prepared
as described (14–16). Overlapping 20-aa peptides representing
rIRBP and murine peptide 161–180 were synthesized as reported
(17, 18). Polyclonal rabbit and mAbs to IRBP (clone H3B5)
were described (19, 20). 
 
Mycobacterium tuberculosis
 
 (strain H37RA)
was from Difco. 
 
Bordetella pertussis
 
 toxin and complete Freund’s
adjuvant (CFA) were from Sigma-Aldrich. RPMI 1640 medium
was from BioWhittaker and was supplemented as described (21).
The monoclonal anti-CD25 antibodies 7D4 and PC61 (FITC la-
beled) and anti-CD4 (PE labeled) for flow cytometry were from
BD Biosciences. PC61 and 7D4 for in vivo use were (respec-
tively) purchased from Serotec or produced in house using an
Integra CL 1000 culture system (Integra Biosciences) following
manufacturer’s protocol.
 
Immunocytochemistry.
 
Frozen sections of eyes were immu-
nostained for IRBP using the Vectastain Elite ABC (peroxidase)
kit from Vector Laboratories and polyclonal anti–monkey IRBP
(1:5,000). Frozen sections of thymus from 8–10-wk-old mice
were stained using H3B5 mAbs (1:200) and the mouse-on-mouse
Innogenex Iso-IHC kit with the following modifications: slides
were air dried (30 min), fixed in acetone (7 min), saturated with
H
 
2
 
O
 
2
 
 (0.3% in PBS), and washed with PBS instead of water. In-
cubation with the substrate buffer was for 20 s. Dehydration was
through graded ethanol series and then dipping through three
changes of xylene. Tissue sections were incubated with the anti-
body for 60 min before visualization of the antigen per manufac-
turers’ instructions.
 
RT-PCR Analysis of IRBP Expression.
 
Areas of 5–10 cells
containing IRBP-positive or adjacent negative cells were micro-
dissected from thymus sections immunostained as described under
microscopic visualization. Total RNA was isolated from 10–20
microdissected samples using the PicoPure RNA isolation kit
(Arcturus). First strand cDNA synthesis was done with 1 
 
 
 
g of
total RNA using the Advantage RT for PCR kit from CLON-
TECH Laboratories. For PCR, 2–5 
 
 
 
l of the cDNA synthesis re-
action was used as template. IRBP cDNA transcripts were ampli-
fied using the forward and reverse primers as described (11).
Control 18S ribosomal RNA transcripts were amplified using the
primer kit from Ambion.
 
Thymectomy, Thymus Grafting, Immunoablation, and Reconstitu-
tion.
 
Mice were thymectomized at 4–6 wk of age by aspiration
of both thymic lobes through a small incision in the skin just
above the sternum. Lack of thymic remnant was confirmed by
autopsy. Thymus grafting was performed 2–4 wk later by placing
two to three lobes of neonatal (less than 72 h old) thymus under
the left kidney capsule. Mice were then gamma irradiated (950
rads from a cesium source) and injected i.v. with syngeneic BM
cells (15–20 
 
 
 
 10
 
6
 
 per animal). Recipient mice were given oxy-
tetracycline (0.4 mg/ml) in drinking water for 4 wk after irradia-
tion and BM infusion and were allowed to reconstitute for 8–16
wk. Alternatively, recipients were thymectomized at 3 wk of age,
implanted with neonatal thymus without immunoablation, and
used 2–3 mo later.
 
Depletion of CD25
 
 
 
 Cells.
 
Depletion of CD25
 
 
 
 cells was
performed essentially as described (22). Briefly, mice were given
two i.p. injections, 3 d apart, of 0.5 mg of the anti-CD25 mAb
7D4 (IgM isotype). This treatment reduced CD4
 
 
 
CD25
 
 
 
 T cells
in the spleen from 
 
 
 
10% to less than 0.1% as assayed by flow cy-
tometry on gated CD4
 
 
 
 cells with anti-CD25 mAb PC61, which 
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is specific to a different epitope of the IL-2 receptor. In an alter-
native protocol, mice were depleted of CD25
 
 
 
 cells by three in-
jections of 1 mg PC61 antibody every other day (23), and effi-
ciency of depletion was confirmed by flow cytometry with 7D4.
 
Immunizations, EAU Induction, and EAU Scoring.
 
Mice were
immunized subcutaneously in the thighs and base of the tail
with 25–100 
 
 
 
g of IRBP or 25–50 
 
 
 
g of peptide 161–180 (24).
Native bovine IRBP and rIRBP were used interchangeably as
specified. Bovine and human IRBPs are highly homologous,
immunologically crossreactive with each other, and induce sim-
ilar disease when injected into mice. rIRBP was preferred in ex-
periments where responses were to be recalled subsequently by
overlapping peptides, which are derived from the human se-
quence. The antigen was emulsified in 0.2 ml emulsion in CFA
supplemented with 
 
M. tuberculosis
 
 strain H37RA to 2.5 mg/ml.
Mice immunized with peptide also received 0.5 
 
 
 
g 
 
Bordetella
pertussis
 
 toxin by i.p. injection. In some experiments, EAU was
induced by adoptive transfer of cells collected from IRBP-
primed donors 12 d after immunization and stimulated in cul-
ture with IRBP or with its component peptides essentially as
described (24). Clinical disease was evaluated by fundoscopy.
Eyes were harvested for histopathology 21 d after immunization
or 14 d after adoptive transfer. Disease was scored in a masked
fashion by an ophthalmic pathologist (C.-C. Chan), on a scale of
0 (no disease) to 4 (maximum disease) in half-point increments,
according to a semiquantitative system described previously
(24, 25).
 
Determination of Immunological Responses.
 
Delayed type hyper-
sensitivity (DTH) to IRBP was evaluated by the ear swelling as-
say (18). Serum antibodies to IRBP were measured by ELISA
(26) 14 d after immunization. For antigen-specific lymphocyte
proliferation and cytokine production in primary cultures, the
spleen and draining LNs (inguinal and iliac) of individual mice
were collected 2 wk after immunization and were cultured with
antigen as described (21). Short term T cell lines from IRBP-
primed mice were derived by three cycles of stimulation with 2
 
 
 
g/ml peptide and IL-2–driven expansion, essentially as de-
scribed (18), before being tested in a proliferation assay. Prolifer-
ation was determined by 
 
3
 
H-thymidine uptake. Cytokines were
quantitated in 48-h antigen-stimulated supernatants using the
Pierce Chemical Co. multiplex SearchLight™ Arrays technol-
ogy (27) (http://www.SearchLightOnline.com). In some of
the experiments, IFN-
 
 
 
 production was determined by con-
ventional ELISA using antibody pairs from Endogen (21, 28).
Antigen-specific cell frequency was assayed by ELISPOT for
IL-2 and IFN-
 
 
 
–producing cells essentially as described (29).
Spots were counted using the ImmunoSpot series 1.0 analyzer
(CTL).
 
Reproducibility and Statistical Analyses.
 
Statistical analysis of
EAU scores was done using the Snedecor and Cochran z test for
linear trend in proportions (nonparametric, frequency based) (30).
Each mouse (average of both eyes) was treated as a statistical
event. DTH, lymphocyte proliferation, and cytokine data were
analyzed by independent 
 
t
 
 test. Probability values 
 
 
 
0.05 were
considered significant.
 
Results
 
IRBP KO Mice Lack IRBP Expression in the Retina and Are 
Resistant to IRBP-induced Uveitis
 
IRBP KO mice lack the promoter region and exon 1 of
IRBP but retain 19% of the IRBP coding sequence and
transcribe mRNA from this sequence (13). We examined
whether any IRBP-crossreactive material is detectable in
the retina of the KO mice using polyclonal antibodies to
IRBP. Although strong immunoreactivity was present in
the WT, no staining was seen in KO retina (Fig. 1). To ad-
dress the possibility that a putative IRBP fragment, unde-
tectable by antibodies, might be present and serve as a tar-
get for EAU, IRBP KO mice and WT controls were
immunized with an aggressive uveitogenic regimen of
IRBP—up to 100 
 
 
 
g of IRBP or 50 
 
 
 
g of peptide 161–
180, the major T cell epitope associated with EAU in
B10.RIII (H-2
 
r
 
) mice (18). This regimen is considerably
more intense than normally required to induce EAU in the
highly susceptible B10.RIII strain. WT B10.RIII mice de-
veloped uveitis within 8–9 d as reported previously (28). In
contrast, IRBP KO mice were completely healthy when
the experiment was terminated on day 21 (Fig. 1). These
data confirm that neither IRBP nor any other crossreactive
protein that could serve as a target for EAU is present in
IRBP KO mice.
Figure 1. IRBP KO mice fail to express residual IRBP in the eye and
are resistant to EAU. (a and b) Retinal sections of WT and KO mice,
respectively, stained with polyclonal anti-IRBP antibody. Only the WT
retina stains positive. (c and d) Histology of WT and KO eyes, respec-
tively, after immunization of mice with IRBP. Only the WT (c) develop
disease. Note inflammatory cells in the retina and vitreous (V), and damage
of the photoreceptor layer (P) and of the outer nuclear layer (ONL).
Hematoxylin and eosin stained. Original magnification,  400. (e) EAU
scores of IRBP-immunized WT and KO mice. Each point is 1 mouse
(average of both eyes). Data are compiled from three separate experiments. 
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IRBP KO Mice Have Strongly Enhanced Immunological 
Responses and an Expanded T Cell Repertoire to IRBP
 
IRBP KO and WT mice were immunized with IRBP
or peptide 161–180 and were examined for antigen-spe-
cific humoral and cellular responses to the immunizing an-
tigen. Serum antibodies, DTH, proliferation, and produc-
tion of cytokines to IRBP and the 161–180 epitope were
all strongly enhanced in the KO mice (Fig. 2). IFN-
 
 
 
 and
IL-4, representing the Th1 and Th2 arms of the immune
response, respectively, were elevated to a similar extent.
Production of IL-5, IL-6, IL-10, IL-13, and TNF-
 
 
 
 was
also similarly enhanced (not depicted).
Frequency of antigen-specific cells was evaluated by
ELISPOT (Fig. 2, e and j). IRBP KO mice immunized and
recalled with IRBP had a threefold higher frequency of
IFN-
 
 
 
–producing cells than WT (1,048 versus 330). Re-
sponses to IRBP are expected to include a background di-
rected against nonconserved epitopes foreign to the mouse.
In keeping with this, mice immunized with peptide 161–
180 had a 6–20-fold higher frequency of antigen-specific
cells (516 versus 25 per million for IFN-
 
 
 
 and 334 versus
55 per million for IL-2).
In an attempt to discern whether the TCR avidity of the
161–180-specific T cell repertoire in the KO was also in-
creased, we quantitated the antigen sensitivity of 161–180-
specific T cells in WT and KO mice. Short term T cell
lines specific to peptide 161–180 were derived (to circum-
vent the different frequency of T cells having this specific-
ity in the two genotypes), and their proliferative response
to graded doses of the antigen presented on irradiated syn-
geneic splenocytes was tested. The dose–response of the
KO cells was down-shifted by an order of magnitude com-
pared with WT, such that they required a 10
 
 
 
 lower dose
of antigen to mount an equivalent proliferative response
(not depicted). Although this is not a direct measurement
of TCR avidity, it nevertheless strongly suggests that the
average TCR avidity of the KO-derived T cell population
was higher.
The ability of KO cells to induce EAU was evaluated
after adoptive transfer into IRBP-sufficient hosts. WT or
IRBP KO donors were immunized with IRBP. Pooled
spleen and LN cells were restimulated in culture with
IRBP, and a fixed number of cells were infused into naive
WT recipients. Recipients of cells from WT mice devel-
oped a moderate form of EAU, with a later onset (day 6–7)
and lower scores (Fig. 3). In contrast, recipients of cells
from KO mice developed an exacerbated form of EAU
characterized by early onset (day 4), elevated scores, and
high incidence. This enhanced pathogenicity could be
due to a greater frequency of effector cells in the IRBP
KO as indicated by ELISPOT data, but it is also possible
that on a per cell basis KO effector T cells could be more
Figure 2. Humoral and cellular responses are increased in IRBP KO mice. Mice were immunized with IRBP (a–e) or with peptide 161–180 (f–j).
Spleens were used for proliferation and cytokine production, whereas LNs were used for ELISPOT. All data represent individual mice or averages of
individual mice   SE. (a and f) Antibody titers (ELISA, OD 490 nm) are averaged of four to five individual mice   SE corrected for background in
normal mouse sera. (b and g) DTH is the difference in microns between the antigen- and the PBS-injected ears. Responses are significantly higher in KO
(P   0.025). Horizontal bars represent the mean of each group. (c and h) Proliferation to the immunizing antigen was significantly elevated in the KO
compared with WT (P   0.001). Data are mean counts per minute (CPM)   SE of triplicate cultures. Results are averaged from three separate experi-
ments including nine WT and seven KO mice. (d and i) Cytokines produced in response to the immunizing antigen were tested using the multiplex
Pierce SearchLight™ array technology. IL-2, IL-4, and IFN-  are elevated in KO over WT (**P   0.001; *P   0.02). Data are composites of three
separate experiments. (e and j) Frequency of IFN-  and IL-2–producing cells by ELISPOT. Shown are spots per million cells, averaged from triplicate
cultures of individual mice (at least three mice per group; P   0.001). 
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potent than those of WT, owing to a higher apparent
TCR avidity.
To assess whether KO and WT mice have differences in
recognition of IRBP epitopes, mice were immunized with
rIRBP and primed spleen cells were restimulated in culture
with overlapping peptides spanning the entire sequence of
rIRBP. Responses in KO mice appeared slightly higher
across the entire panel with significant changes apparent
in responses to peptide 161–180, the major pathogenic
epitope recognized by WT mice, and peptide 121–140,
which elicited a response in KO but not in WT splenocytes
(Fig. 4). To evaluate whether 121–140 represented a
pathogenic specificity that is eliminated in the WT, we
infused peptide 121–140-restimulated cells taken from
IRBP-primed KO donors into WT recipients. All WT re-
cipients (
 
n
 
 
 
  
 
6 in two experiments) developed bilateral
EAU, with 40 
 
 
 
 10
 
6
 
 cells eliciting mild to moderate dis-
ease (scores up to 1) and 80 
 
 
 
 10
 
6
 
 cells eliciting severe dis-
ease (scores up to 3). Enhanced responsiveness to IRBP,
enhanced uveitogenicity, and an altered IRBP epitope rec-
ognition were also observed in T cells of IRBP KO mice
on the C57BL/6 background (31).
 
EAU-susceptible WT Mice Express IRBP in the Thymus
 
A previous study was unable to detect IRBP in thymic
extracts of EAU-susceptible B10.RIII mice using PCR and
Western blotting, although under the same conditions clear
signals were detected in resistant strains (11). We reexam-
ined this issue here using a sensitive and highly optimized
immunohistochemical staining. Frozen sections from thymi
of naive WT or KO mice were stained using the monoclo-
nal anti-IRBP antibody H3B5 (20). Sparse positively stain-
ing cells were detected in WT thymi but were absent in
KO thymi (Fig. 5, a and b). The IRBP-positive cells were
rare and appeared unevenly distributed: only 17 out of the
50 WT sections examined contained positively staining
cells. They were usually seen in the thymic medulla or at
the cortico–medullary junction and often appeared in clus-
ters of several cells. Discrete dark striations in the cytoplasm
could often be discerned (Fig. 5, a, insets). Positively stain-
ing cells and neighboring negative areas were carefully mi-
crodissected, and pools of 10–20 picks were subjected to
Figure 3. Primed lymphoid cells of IRBP KO mice induce exacerbated
EAU in IRBP-sufficient recipients. Lymphocytes from IRBP-immunized
KO or WT mice were cultured with IRBP and were infused into naive
WT recipients (30   106 per mouse). Eyes collected 14 d after adoptive
transfer were scored by histopathology. (a) EAU scores in recipients of
cells from WT or KO donors. (b and c) Histopathology of eyes revealed
severe retinal damage in recipients of KO cells (b) and only mild damage
in recipients of WT cells (c). Hematoxylin and eosin stained. Original
magnification,  400.
Figure 4. T cell epitope recognition by WT and IRBP KO mice.
Spleen cells of mice immunized with rIRBP (25  g in CFA) were har-
vested on day 14 and were stimulated in culture with overlapping 20-aa
peptides of rIRBP (10  M). Data are presented as   CPM   SE of triplicate
cultures for each peptide tested (averaged results are from five individual
mice tested in each experimental group). Highly significant changes (P  
0.001) were seen in responses to peptide 161–180 (arrows) and peptide
121–140 (arrowheads). 
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RT-PCR using IRBP-specific primers. IRBP message was
detectable only in the immunopositive areas (Fig. 5 c). No
IRBP signal was detectable in microdissected cells from
IRBP KO thymi (not depicted).
 
Thymic Expression of IRBP Confers Immunological Tolerance 
and Raises the Threshold of Susceptibility to Retinal 
Autoimmune Disease
 
To address the functional significance of thymic IRBP
expression, we performed thymus transplantation between
WT and KO mice. Thus, paired sets of mice were prepared
that had an identical periphery but differed by thymic ex-
pression of IRBP: KO recipients of either WT or KO thy-
mus (KO
 
WT
 
 versus KO
 
KO
 
) and WT recipients of either
WT or KO thymus (WT
 
WT
 
 versus WT
 
KO
 
). Although both
types of recipients could be used to analyze immunological
responses, WT recipients also provided the opportunity to
examine the impact of thymic IRBP expression on the
ability to develop EAU.
 
KO Recipients.
 
KO mice were adult thymectomized,
transplanted with either WT or KO thymus under the kid-
ney capsule, lethally irradiated, and reconstituted with
matching (KO) BM cells. The mice were immunized 2–4
mo after immunoablation and BM reconstitution with
rIRBP. Responses were recalled in vitro with the whole
protein (Fig. 6 a) or with peptide 161–180 (Fig. 6, b–d).
KO recipients of WT (KO
 
WT
 
) thymus had reduced immu-
nological responses compared with their KO
 
KO
 
 counter-
parts. As in the unmanipulated mice, tolerance affected the
pathogenic 161–180 T cell epitope, as judged by prolifera-
tion and ELISPOT assay for IFN-
 
 
 
– and IL-2–producing
cells (Fig. 6 d). Responses of splenocytes from these mice
to overlapping peptides representing the entire length of
rIRBP were lower across the board, with a particularly
prominent reduction of the response to peptide 161–180
(not depicted). Thus, the pattern of immunological re-
sponses to IRBP followed the donor of the thymus.
 
WT Recipients.
 
Conversely, WT recipients of KO
thymi (immunoablated, reconstituted, and challenged with
rIRBP as above) developed strongly enhanced immuno-
logical responses to IRBP (Fig. 6 e). This enhancement
specifically included peptide 161–180 as evidenced by lym-
phocyte proliferation and by frequency of IL-2– and IFN-
 
 
 
–producing cells (Fig. 6, f–h). Splenocyte responses of
these mice to overlapping rIRBP peptides were elevated
across the board and to peptide 161–180 in particular (not
depicted). Notably, WT recipients of KO thymus devel-
oped highly exacerbated EAU characterized by early onset
and high disease scores (Table I). Disease in recipients of
KO thymus was so severe that the experiments had to be
terminated a week early, 14 d after immunization.
Because the high dose of irradiation may damage the
blood-retinal barrier and affect the ability of the mice to
develop EAU, it was important to rigorously confirm these
data in WT mice that had not been irradiated (Fig. 6, i–l).
Therefore, WT mice thymectomized at weaning were
transplanted with a neonatal thymus and were immunized
with peptide 161–180 2 mo later. These early thymecto-
mized mice, which had not been immunoablated, pos-
sessed a mixed WT plus KO T cell compartment. Never-
theless, even such a partial KO repertoire was sufficient to
cause a profound enhancement of immunological responses
(Fig. 6, i–l). These mice also developed an exacerbated dis-
ease after immunization with peptide 161–180 or with
whole IRBP (Fig. 7). Their individual disease scores are in-
cluded in Table I.
 
Thymic Control of Susceptibility to IRBP-induced EAU Includes 
a Role for CD4
 
 
 
CD25
 
 
 
 Regulatory T Cells
 
The thymus controls autoimmune responses not only by
culling high-affinity self-reactive precursor-effector cells
but also by releasing CD4
 
 
 
CD25
 
 
 
 T regulatory cells (32,
33). Our early thymectomized nonimmunoablated WT re-
cipients are expected to have functional CD25
 
  T regula-
tory cells, since such cells are released by the thymus during
Figure 5. WT B10.RIII mice express IRBP mRNA and protein in the
thymus. Frozen thymic sections from unmanipulated WT or KO mice
were immunostained with monoclonal anti-IRBP antibody. Sparse positive
cells (enlarged in insets) were detectable in WT thymi (a) but were absent
in KO thymi (b). IRBP-positive and negative areas microdissected from
WT thymic sections were amplified by RT-PCR using IRBP and 18S
ribosomal RNA primers. IRBP message was detectable in the immu-
nopositive areas (c, lane 2) but not in the immunonegative areas (c, lane
1). Ocular tissue served as a positive control (c, lane 3).Avichezer et al. 1671
the first week of life. Nevertheless, these mice developed
greatly enhanced disease after receiving a KO thymus trans-
plant, equivalent to mice that had been immunoablated be-
fore transplant. This might be interpreted as evidence
against a role for CD4 CD25  T cells in this model. How-
ever, it is also possible that potent effector-precursor cells
released by the KO thymus might have overwhelmed the
regulatory potential of these cells.
To examine a possible contribution of CD4 CD25 
cells in setting the threshold of susceptibility to EAU, WT
mice were depleted of CD25  cells and were challenged
for EAU by immunization with 5  g of IRBP. At this low
IRBP dose, the untreated control mice developed only
moderate or no disease. In contrast, the CD25-depleted
mice developed 100% disease incidence and severe EAU
scores (Table II). To address the possibility that the CD25 
cells in this experiment were not thymically derived, WT
mice were thymectomized at 4 wk of age, were depleted of
CD25  cells, and then were rested for 4 wk to allow re-
generation of any CD25  regulators that might not be thy-
mically derived. When challenged for EAU, the CD25-
depleted mice again developed significantly more disease
than their nondepleted counterparts, supporting a thymic
origin for the regulatory CD25  cells (Table II).
Discussion
Tolerance to immunologically privileged antigens that re-
side behind blood-tissue barriers, such as the eye and the
brain, is still not understood completely. Studies in “shiverer”
mice that lack myelin basic protein revealed that endogenous
myelin basic protein expression is tolerogenic and alters the T
cell repertoire selection (29, 34). The present study was un-
dertaken to directly address the question whether tolerance to
antigens residing in the retina of the eye can be demonstrated
in mice that are susceptible to retinal autoimmunity. Previous
Figure 6. WT recipients of KO thymus grafts have enhanced immunological responses compared to recipients of WT grafts. Adult thymectomized
KO (a–d) or WT (e–h) recipients grafted with a mismatched or homologous thymus were immunoablated by irradiation and reconstituted with homologous
BM and were subsequently immunized with rIRBP. Alternatively, WT mice thymectomized at weaning (i–l) were grafted with a mismatched or homol-
ogous thymus without immunoablation and were immunized with peptide 161–180. Mice were tested for immunological responses essentially as described
in Fig. 2, except for IFN-  secretion, which was determined by conventional ELISA. Note that in all panels the grafted thymus genotype is denoted as a
superscript. Both humoral responses (a, e, and i) and cellular responses (b–d, f–h, and j–l) were upregulated in all the recipients of KO thymi compared
with recipients of WT thymi, irrespective of the IRBP sufficiency status of the recipient. (**P   0.005; *P   0.05;  , P   0.1).Central Tolerance to a Privileged Retinal Antigen 1672
data pointed to an association between presence of a particu-
lar retinal antigen in the thymus and resistance to EAU in-
duced by immunization with that antigen (11). However, the
questions regarding uveitogenic antigens whose thymic ex-
pression is below the sensitivity of conventional assays could
not be addressed until susceptible mice deficient for the target
antigen became available.
It was first necessary to ascertain that the IRBP KO
mice, which retain part of the IRBP gene, indeed fail to
express antigenic protein transcribed from this sequence.
This appeared to be the case, both by lack of immunoreac-
tive material in the retina and by the resistance of these
mice to an aggressive regimen of immunization with
IRBP. Additionally, the immunological responses to IRBP
Table I. WT Recipients of IRBP KO Thymi Develop More Severe EAU than Recipients of WT Grafts
Graft origin Individual EAU scoresa Median Mean   SE P valueb
Immunization with:
Peptide 161–180c
WT (0, 0) (0, 0.5) (0, 0.5) 0.25 0.4   0.2
(0, 0.5) (0, 0.5) (1, 2)
KO (2, 2) (2, 2.5) (2.5, 2.5) 2.5 2.9   0.3  0.0005
(2.5, 2.5) (2.5, 3) (3, 3)
(4, 4) (4, 4)
IRBPd
WT (0.5, 0.5) (2, 2) 1.25 1.25   0.75
KO (3, 3.5) (4, 4) 3.75 3.6   0.4  0.012
rIRBPe
WT (0.5, 0.5) (0.5, 0.5) (0.5, 0.5) 0.5 0.5 
KO (0.5, 0.5) (1.5, 2) (2, 2) (2, 2) 2.0 1.6   0.4
aValues in parentheses represent EAU scores in individual eyes of each mouse.
bLinear trends in proportions versus WT grafted with WT thymus (P   0.05 is significant).
cMice were thymectomized at 3 wk of age, grafted with a neonatal thymus, and immunized 2–3 mo later with peptide 161–180 (25–50  g in CFA)  
PTX.
dMice were thymectomized at 3 wk of age, grafted with a neonatal thymus, and immunized 3 mo later with IRBP (25  g in CFA).
eMice were thymectomized at 4–5 wk of age, grafted with neonatal thymus, immunoablated and BM reconstituted, and immunized 4 mo later with
rIRBP (25  g in CFA).
Table II. CD25 Depletion Results in Enhancement of EAU Scores 
Experiment no. Treatment Individual EAU scoresa Median Mean   SE P valueb
1 Nonthymectomizedc
CD25 depleted (2.5, 2.5) (2.5, 2.5) 2.5 2.7   0.1  0.009
(3, 3) (3, 2.5) 
Untreated control (0, 0) (0.5, 0.75) 0.3 0.5   0.4
(0, 0) (1.5, 1.5)
2 Thymectomizedd
CD25 depleted (1.5, 2) (2, 2) 2.0 2.5   0.4  0.027
(3, 3) (3.5, 3)
Untreated control (0.5, 0.75) (0, 0.75) 0.6 0.7   0.5
(2.5, 2.5) (0, 0) (0, 0)
aValues in parentheses represent EAU scores in individual eyes of each mouse.
bLinear trends in proportions of depleted versus control (P   0.05 is significant).
cMice were depleted of CD25  cells with PC61 antibodies (23) and were immunized for EAU induction with IRBP (5  g in CFA).
dMice thymectomized at 4 wk of age were depleted of CD25  cells with 7D4 antibodies (22), rested for 4 wk after depletion, and immunized for
EAU with IRBP (10  g in CFA).Avichezer et al. 1673
of IRBP KO mice were elevated across the board, imply-
ing lack of systemic tolerance to this molecule. Thus, EAU
susceptible WT mice displayed a detectable level of toler-
ance not present in the KO.
We then decided to examine the thymus of B10.RIII
WT and KO mice for IRBP expression. PCR analysis of
thymic extracts, under the conditions used by Egwuagu et
al. (11) to detect IRBP in resistant but not susceptible
mouse strains failed to detect an IRBP signal, confirming
what had been published. However, looking at individual
cells by immunohistochemistry and microdissection, posi-
tive IRBP signals at the protein and the mRNA levels were
detected in scattered cells in the medulla and cortico–med-
ullary junction of WT thymus that were absent in KO thy-
mus. Although we did not identify the cell type expressing
IRBP in the thymus, it is likely that those were thymic
medullary epithelial cells, as reported by others (35–37).
Thymus transplantation between WT and KO mice pro-
vided direct evidence that this level of thymic expression is
functionally significant in terms of setting the threshold of
responsiveness to IRBP in general and the threshold of sus-
ceptibility to EAU in particular. Importantly, this included
control of the response to the disease-relevant peptide 161–
180, which is the single most dominant uveitogenic IRBP
epitope for WT B10.RIII mice and accounts for much of
the uveitogenicity of whole IRBP in that strain (10). The
frequency of p161–180-specific cells in WT mice and their
apparent avidity was markedly reduced compared with the
KO. It appears, therefore, that the 161–180-specific re-
sponse that drives IRBP-induced EAU in WT mice repre-
sents a residuum of the original T cell repertoire generated
to this epitope. The IRBP KO thymus might also per-
mit  retention of pathogenic repertoires to other IRBP
epitope(s) eliminated in the WT, such as peptide 121–140.
Figure 7. EAU in WT recipients of IRBP
KO thymi is greatly enhanced compared with
mice grafted with WT thymi. Early thymecto-
mized mice were immunized with IRBP or
161–180 peptide 4 wk after transplantation with
WT (a–c, g, and h) or KO (d–f, i, and j) thymus.
Histology was performed 21 d after immuniza-
tion. Hematoxylin and eosin stained. Original
magnification,  400.Central Tolerance to a Privileged Retinal Antigen 1674
Thymic control of T cell responses in the periphery in-
volves not only the direct elimination of pathogenic cells
but also the release of regulatory cells that control tissue-
specific autoimmunity (for review see 32). It is thought that
the relevant tissue antigen must be expressed in the thymus
to permit generation of specific CD4 CD25  regulatory T
cells (33). Enhanced responses to IRBP in mice bearing an
IRBP KO thymus might therefore be attributable not only
to culling of IRBP-reactive precursor-effector cells but also
to lack of generation of CD25  regulatory T cells specific to
IRBP. It is important to point out in this context that al-
though the protective role of CD25  regulatory cells is well
established in spontaneous autoimmunity models, it has
been more difficult to demonstrate in induced models of
autoimmunity and has not thus far been demonstrated in
EAU. Furthermore, the eye elicits its own, highly special-
ized, immunoregulatory circuits that could make thymically
derived CD25  regulatory cells redundant (5–7, 38). Our
finding that immunocompetent WT mice, deprived of thy-
mus-dependent CD25  regulatory cells, develop enhanced
EAU scores, strongly supports a contributing role for these
cells in setting the threshold of EAU susceptibility.
A role for peripheral mechanisms in self-tolerance to
uveitogenic retinal antigens is still in question. Expression
of retina-specific proteins is largely restricted to the eye,
where blood-tissue barriers prevent free traffic of lympho-
cytes. Thus, peripheral tolerance by continuous exposure
of potentially autoreactive T cells to tissue antigens in a
noninflammatory milieu is unlikely to operate efficiently
for retinal antigens. Indeed, we and others have demon-
strated that responses to retina-specific antigens are dramat-
ically reduced if their immune-privileged status is revoked
by expressing them extraocularly (8–10). It is still unre-
solved whether the ACAID phenomenon, which is well
studied with relation to injected proteins (5, 6), is elicited
by native retinal antigens residing in the intact eye. Greger-
son et al. have proposed this to be the case based on re-
duced responsiveness to  -galactosidase in mice expressing
this protein as a neo-antigen on a retina-specific promoter
(39), but they have not performed thymus transplants or
CD25  cell depletion to rigorously exclude central toler-
ance. Our results in mice immunoablated by irradiation
clearly showed that WT mice given a KO thymus (whose
only source of IRBP is the periphery), develop significant
tolerance to IRBP compared with KO mice given a KO
thymus (compare WTKO to KOKO mice in Fig. 6, a–h).
However, although this demonstrates that peripheral toler-
ance can be induced in mice that have no thymic source of
IRBP, it does not prove that the intact eye elicits such tol-
erance, since we cannot exclude the possibility that changes
in the blood-retinal barrier resulting from irradiation have
altered the accessibility of the ocular compartment. The
question of peripheral tolerance by the intact eye is being
addressed in a separate study.
Our current data complement and extend recent studies
on thymic tolerance to proteolipid protein (PLP), one of
the antigens driving disease in the experimental autoim-
mune encephalomyelitis model. Seminal studies by Klein et
al. (40) and by Anderson et al. (41) revealed predominant
expression in the thymus of DM20, a shortened splice vari-
ant of PLP message that lacks the region encoding the 139–151
epitope, instead of the full-length molecule that is ex-
pressed in the brain. This thwarts deletion of 139–151-spe-
cific T cells and explains the susceptibility of SJL/J mice to
experimental autoimmune encephalomyelitis induced by
this epitope but not by other PLP epitopes that are repre-
sented in the thymus. Unlike PLP, in the case of IRBP
there is no evidence, either by PCR or by Western blot-
ting, that the molecule expressed in the thymus represents a
different splice variant than the one expressed in the eye
(11). Therefore, despite presence of full-length IRBP de-
monstrable at the protein level, elimination of pathogenic
specificities is inadequate, although at the same time appar-
ently permitting positive selection of CD25  regulatory
cells. These results raise a concept that the balance of au-
toimmune effectors versus regulators generated by the thy-
mus may represent a sliding scale that is influenced by
quantitative aspects of thymic autoantigen expression.
In summary, the present study for the first time provides
direct evidence that uveitis-susceptible WT mice express
low levels of their target antigen in the thymus. This level
of expression, although undetectable by conventional as-
says, is immunologically relevant and serves to raise the
threshold of immunological responsiveness and of suscepti-
bility to disease. The mechanism appears to involve culling
of precursor effector cells and generation of CD4 CD25 
regulatory cells by the thymus. These data provide new in-
sights into regulation of responsiveness and autoimmune
susceptibility to immunologically privileged self-antigens.
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